OpenLB
Open Library of Bioscience
Advanced Search
International journal of molecular sciences
Nov 24, 2022;23 (23):

Optimal Intravenous Administration Procedure for Efficient Delivery of Canine Adipose-Derived Mesenchymal Stem Cells.

Yuyo Yasumura, Takahiro Teshima, Yoshiaki Taira, Takahiro Saito, Yunosuke Yuchi, Ryohei Suzuki, Hirotaka Matsumoto
Author Information
  1. Yuyo Yasumura: Laboratory of Veterinary Internal Medicine, Department of Veterinary Clinical Medicine, School of Veterinary Medicine, Faculty of Veterinary Science, Nippon Veterinary and Life Science University, 1-7-1 Kyonan-cho, Musashino, Tokyo 180-8602, Japan. ORCID
  2. Takahiro Teshima: Laboratory of Veterinary Internal Medicine, Department of Veterinary Clinical Medicine, School of Veterinary Medicine, Faculty of Veterinary Science, Nippon Veterinary and Life Science University, 1-7-1 Kyonan-cho, Musashino, Tokyo 180-8602, Japan. ORCID
  3. Yoshiaki Taira: Laboratory of Veterinary Internal Medicine, Department of Veterinary Clinical Medicine, School of Veterinary Medicine, Faculty of Veterinary Science, Nippon Veterinary and Life Science University, 1-7-1 Kyonan-cho, Musashino, Tokyo 180-8602, Japan.
  4. Takahiro Saito: Laboratory of Veterinary Internal Medicine, Department of Veterinary Clinical Medicine, School of Veterinary Medicine, Faculty of Veterinary Science, Nippon Veterinary and Life Science University, 1-7-1 Kyonan-cho, Musashino, Tokyo 180-8602, Japan.
  5. Yunosuke Yuchi: Laboratory of Veterinary Internal Medicine, Department of Veterinary Clinical Medicine, School of Veterinary Medicine, Faculty of Veterinary Science, Nippon Veterinary and Life Science University, 1-7-1 Kyonan-cho, Musashino, Tokyo 180-8602, Japan. ORCID
  6. Ryohei Suzuki: Laboratory of Veterinary Internal Medicine, Department of Veterinary Clinical Medicine, School of Veterinary Medicine, Faculty of Veterinary Science, Nippon Veterinary and Life Science University, 1-7-1 Kyonan-cho, Musashino, Tokyo 180-8602, Japan. ORCID
  7. Hirotaka Matsumoto: Laboratory of Veterinary Internal Medicine, Department of Veterinary Clinical Medicine, School of Veterinary Medicine, Faculty of Veterinary Science, Nippon Veterinary and Life Science University, 1-7-1 Kyonan-cho, Musashino, Tokyo 180-8602, Japan.
PMID: 36499004 DOI: 10.3390/ijms232314681

Abstract

Mesenchymal stem cells (MSC) are currently being investigated for their therapeutic applications in a wide range of diseases. Although many studies examined peripheral venous administration of MSC, few have investigated the detailed intravenous administration procedures of MSC from their preparation until they enter the body. The current study therefore aimed to explore the most efficient infusion procedure for MSC delivery by preparing and infusing them under various conditions. Canine adipose-derived mesenchymal stem cells (cADSC) were infused using different infusion apparatuses, suspension solutions, allogenic serum supplementation, infusion time and rates, and cell densities, respectively. Live and dead cell counts were then assessed by manual measurements and flow cytometry. Efficiency of live- and dead-cell infusion and cell viability were calculated from the measured cell counts and compared under each condition. Efficiency of live-cell infusion differed significantly according to the infusion apparatus, infusion rate, and combination of cell density and serum supplementation. Cell viability after infusion differed significantly between the infusion apparatuses. The optimal infusion procedure resulting in the highest cell delivery and viability involved suspending cADSC in normal saline supplemented with 5% allogenic serum at a density of 5 × 10 cells/mL, and infusing them using an automatic infusion device for 15 min. This procedure is therefore recommended as the standard procedure for the intravenous administration of ADSC in terms of cell-delivery efficiency.

Keywords

adipose-derived mesenchymal stem cells canine cell delivery cell viability intravenous administration

References

  1. Cell Transplant. 2013;22(6):1075-86 [PMID: 23043973]
  2. Cytotherapy. 2006;8(4):315-7 [PMID: 16923606]
  3. BMC Vet Res. 2022 Jan 7;18(1):26 [PMID: 34996443]
  4. PeerJ. 2017 May 17;5:e3301 [PMID: 28533959]
  5. J Biomed Mater Res A. 2008 Jul;86(1):228-34 [PMID: 17975816]
  6. J Tissue Eng Regen Med. 2008 Oct;2(7):436-44 [PMID: 18720444]
  7. Clin Transl Med. 2021 Feb;11(2):e297 [PMID: 33634996]
  8. Blood. 2012 Oct 25;120(17):3436-43 [PMID: 22966167]
  9. Cell Transplant. 2009;18(10):1111-21 [PMID: 19650972]
  10. Stem Cells Transl Med. 2020 Jan;9(1):17-27 [PMID: 31804767]
  11. Stem Cells Int. 2016;2016:4709572 [PMID: 26779263]
  12. Cytotherapy. 2017 Aug;19(8):927-936 [PMID: 28662983]
  13. Int J Hematol. 2016 Feb;103(2):243-50 [PMID: 26608364]
  14. Stem Cells. 2016 Jul;34(7):1709-29 [PMID: 27066769]
  15. Stem Cell Res Ther. 2021 Mar 18;12(1):192 [PMID: 33736695]
  16. Exp Cell Res. 2015 Dec 10;339(2):231-40 [PMID: 26586565]
  17. PeerJ. 2016 Mar 22;4:e1773 [PMID: 27019778]
  18. AJNR Am J Neuroradiol. 2010 Sep;31(8):1488-92 [PMID: 20395386]
  19. Cytotherapy. 2017 Jan;19(1):36-46 [PMID: 27856228]
  20. Stem Cell Res Ther. 2017 Oct 3;8(1):218 [PMID: 28974260]
  21. Ann Neurol. 2005 Jun;57(6):874-82 [PMID: 15929052]
  22. Br J Anaesth. 2011 Jan;106(1):51-6 [PMID: 21051494]
  23. Adv Sci (Weinh). 2021 Feb 24;8(7):2002944 [PMID: 33854883]
  24. Cell Transplant. 2015;24(3):339-47 [PMID: 25622293]
  25. Stem Cells Dev. 2009 May;18(4):533-43 [PMID: 19055360]
  26. Adv Wound Care (New Rochelle). 2021 Jan;10(1):24-48 [PMID: 32470315]
  27. Mol Ther. 2018 Jul 5;26(7):1610-1623 [PMID: 29807782]
  28. PM R. 2016 Sep;8(9):844-54 [PMID: 26826615]
  29. Int J Mol Sci. 2019 May 15;20(10): [PMID: 31096604]
  30. J Embryol Exp Morphol. 1966 Dec;16(3):381-90 [PMID: 5336210]
  31. J Am Acad Dermatol. 2020 Aug;83(2):447-454 [PMID: 31786163]
  32. J Clin Oncol. 2016 Aug 20;34(24):2843-50 [PMID: 27400949]
  33. Stem Cells Int. 2017;2017:3892514 [PMID: 29445402]
  34. Tissue Eng Part C Methods. 2010 Oct;16(5):989-97 [PMID: 20001789]
  35. Stem Cell Res Ther. 2013 Apr 30;4(2):48 [PMID: 23632128]
  36. Cells. 2019 Aug 13;8(8): [PMID: 31412678]
  37. J Am Coll Cardiol. 2017 Feb 7;69(5):526-537 [PMID: 27856208]
  38. Chest. 2017 May;151(5):971-981 [PMID: 27890713]
  39. J Transl Med. 2018 Mar 9;16(1):57 [PMID: 29523171]
  40. Int J Mol Sci. 2020 Jan 21;21(3): [PMID: 31973182]
  41. Cell Transplant. 2015;24(4):661-72 [PMID: 25807231]
  42. Front Immunol. 2015 Nov 03;6:560 [PMID: 26579133]
  43. Stem Cells Int. 2016;2016:1764938 [PMID: 27022399]
  44. Cytometry A. 2018 Jan;93(1):19-31 [PMID: 29072818]
  45. Cytotherapy. 2016 Feb;18(2):229-41 [PMID: 26794714]
  46. Stem Cell Res Ther. 2020 Feb 3;11(1):43 [PMID: 32014055]
  47. J Transl Med. 2012 Nov 21;10:229 [PMID: 23171323]
  48. In Vitro Cell Dev Biol Anim. 2015 Feb;51(2):142-50 [PMID: 25361717]
  49. J Vet Sci. 2012 Sep;13(3):299-310 [PMID: 23000587]
  50. Regen Med. 2011 Nov;6(6 Suppl):44-51 [PMID: 21999261]
  51. Front Cell Dev Biol. 2022 Apr 13;10:867426 [PMID: 35493074]
  52. J Am Soc Nephrol. 2013 Mar;24(4):587-603 [PMID: 23471196]
  53. Cell Mol Life Sci. 2020 Jul;77(14):2771-2794 [PMID: 31965214]
  54. Sci Adv. 2020 Jul 22;6(30):eaba6884 [PMID: 32832666]
  55. Stem Cell Res Ther. 2020 Dec 1;11(1):519 [PMID: 33261658]
  56. Science. 1987 Oct 23;238(4826):491-7 [PMID: 2821619]
  57. Ann Hematol. 2018 Oct;97(10):1941-1950 [PMID: 29947972]
  58. Biomed Res Int. 2014;2014:951512 [PMID: 24511552]
  59. Plast Reconstr Surg. 2006 Sep;118(3 Suppl):121S-128S [PMID: 16936551]
  60. Circ Res. 2017 Nov 10;121(11):1279-1290 [PMID: 28923793]
  61. Stem Cell Res Ther. 2020 Aug 18;11(1):361 [PMID: 32811531]
  62. Sci Rep. 2018 Jun 15;8(1):9194 [PMID: 29907825]
  63. Biol Blood Marrow Transplant. 2014 Oct;20(10):1580-5 [PMID: 24952358]
  64. Histochem Cell Biol. 2017 Sep;148(3):273-288 [PMID: 28432431]
  65. Gene. 2020 Jan 5;722:144058 [PMID: 31494240]
  66. J Physiol Pharmacol. 2014 Jun;65(3):327-39 [PMID: 24930504]
  67. Cytotechnology. 2008 Oct;58(2):69-75 [PMID: 19002767]
  68. Front Vet Sci. 2020 May 29;7:278 [PMID: 32656249]
  69. Mol Med Rep. 2019 Mar;19(3):2189-2201 [PMID: 30664198]
  70. Tissue Eng Part B Rev. 2014 Oct;20(5):523-44 [PMID: 24552279]
  71. Int J Hematol. 2015 Sep;102(3):368-78 [PMID: 26228529]
  72. Front Immunol. 2019 Apr 02;10:619 [PMID: 31001253]
  73. World J Stem Cells. 2020 Dec 26;12(12):1492-1510 [PMID: 33505597]
  74. Curr Mol Med. 2012 Jun;12(5):574-91 [PMID: 22515979]
  75. J Cell Mol Med. 2021 Nov;25(22):10747-10760 [PMID: 34708529]
  76. PLoS One. 2013 Aug 22;8(8):e72604 [PMID: 23991127]
  77. J Cell Physiol. 2020 Dec;235(12):9185-9210 [PMID: 32452052]

Grants

  1. 21H02373/Japan Society for the Promotion of Science

MeSH Term

Animals
Dogs
Mesenchymal Stem Cell Transplantation
Mesenchymal Stem Cells
Administration, Intravenous
Infusions, Intravenous
Journal Article
Article has an altmetric score of 1

Word Cloud

Created with Highcharts 10.0.0infusioncellMSCadministrationprocedureviabilitystemcellsintravenousdeliveryserumMesenchymalinvestigatedthereforeinfusingCanineadipose-derivedmesenchymalcADSCusingapparatusesallogenicsupplementationcountsEfficiencydifferedsignificantlydensitycurrentlytherapeuticapplicationswiderangediseasesAlthoughmanystudiesexaminedperipheralvenousdetailedprocedurespreparationenterbodycurrentstudyaimedexploreefficientpreparingvariousconditionsinfuseddifferentsuspensionsolutionstimeratesdensitiesrespectivelyLivedeadassessedmanualmeasurementsflowcytometrylive-dead-cellcalculatedmeasuredcomparedconditionlive-cellaccordingapparatusratecombinationCelloptimalresultinghighestinvolvedsuspendingnormalsalinesupplemented5%5×10cells/mLautomaticdevice15minrecommendedstandardADSCtermscell-deliveryefficiencyOptimalIntravenousAdministrationProcedureEfficientDeliveryAdipose-DerivedStemCellscanine

Similar Articles

Cited By